30. Chromosomal microarray analysis work-up for hypocellular MDS patients with inconclusive cytogenetics

Nguyen Hong Ha(Northwestern Medicine), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Awdhesh Kalia(The University of Texas MD Anderson Cancer Center), Hyvan Dang(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Sherin Raju(The University of Texas MD Anderson Cancer Center), Christopher N. Bowman(University of Colorado Boulder), Rajyalakshmi Luthra, Diana Rush(BioNano Genomics (United States)), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Nazneen Ahmed(University of Kent), Fangling Xu(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Peter Hu(The University of Texas MD Anderson Cancer Center), Héctor M. Álvarez(The University of Texas MD Anderson Cancer Center)
Cancer Genetics
October 31, 2023
10.1016/j.cancergen.2023.08.038
Cited by 0

Related Papers

Inhibition of JNK activation through NF-κB target genes
|Nature|2001|719
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
|Blood|2009|718
Click Chemistry in Materials Science
|Advanced Functional Materials|2014|663
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570